Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review

Clin Infect Dis. 2010 Jun 15;50(12):e73-6. doi: 10.1086/653011.

Abstract

Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma. Temozolomide frequently produces profound lymphopenia. We report 2 cases of cytomegalovirus disease that occurred in patients receiving temozolomide therapy and review 4 additional cases reported in the literature. Narrow monitoring with cytomegalovirus antigenemia assay should be considered for recommendation.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Antineoplastic Agents, Alkylating / adverse effects
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Central Nervous System Neoplasms / complications
  • Central Nervous System Neoplasms / drug therapy
  • Cytomegalovirus Infections / complications*
  • Cytomegalovirus Infections / epidemiology
  • Dacarbazine / adverse effects
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / therapeutic use
  • Female
  • Glioblastoma / complications
  • Glioblastoma / drug therapy
  • Humans
  • Lymphoma, B-Cell / complications
  • Lymphoma, B-Cell / drug therapy
  • Male
  • Middle Aged
  • Opportunistic Infections / complications
  • Temozolomide

Substances

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide